A Cost Comparison of Biologic Treatment Regimens for Metastatic Colorectal Cancer in Italy:

Global & Regional Health Technology Assessment

SergioIannazzo¹ 

关键词: Bevacizumab;    Colorectal cancer;    Cost analysis;   

DOI  :  10.5301/grhta.5000274

学科分类：医学（综合）

来源: Sage Journals

【 摘 要 】

IntroductionBevacizumab is a monoclonal antibody, which, in association with combination chemotherapy regimens, has been shown to be active in metastatic colorectal cancer. Other biologic agents active in the same setting are cetuximab and panitumumab, both of which are monoclonal antibodies directed against the antiepidermal growth factor receptor. The objective of this study was to compare treatment costs of first-line regimens for metastatic colorectal cancer in Italy.MethodsA set of first-line regimens was considered, according to the Italian Association of Medical Oncology and the European Society for Medical Oncology guidelines. A targeted review of the literature was undertaken to identify clinical study references for treatment regimens. The total cost of a regimen was calculated in the perspective of the Italian healthcare system summing up drugs, administration, and adverse event costs, based on year 2016 prices and tariffs.ResultsBevacizumab 7.5 mg + capecitabine was the least expensive regimen...

【 授权许可】

CC BY